what are glp 1 drugs Comparing Ozempic, Wegovy and Other GLP-1 Patients' Use GLP-1 Drugs for

GLP-1RAs significantly reduce weight and improve glycaemic control, with emerging benefits for other obesity-related health conditions

A 2023 SELECT trial determined that patients with pre-existing cardiovascular disease who used Wegovy over 39.8 months experienced the following events, compared to patients given a placebo

For those with obesity or type 2 diabetes, this number jumps dramatically to over 50% 18

Mahfooz F, Aylor K, Mathew J Jr, Reichmuth M (2021) Extending our understanding of exenatide: a rare case of angio-oedema

However, triple receptor agonism, or agonism/antagonism combinations, can be achieved not only though unimolecular triple agonists, but also by combining mono- and dual-agonists